Elixir Medical Announces Full Market Release of LithiX HC-IVL System

October 3, 2025—Elixir Medical announced the full market release of its LithiX Hertz Contact (HC) intravascular lithotripsy (IVL) system, as well as commercial milestones and an upcoming presentation on the device at TCT 2025, the Transcatheter Cardiovascular Therapeutics conference.

In April 2025, the company announced CE Mark approval under the European Union Medical Device Regulation and the initial limited-market launch of the device.

Since then, more than 400 patients have been treated with the LithiX HC-IVL system across 16 countries in Europe and Asia and LithiX has been evaluated and is being adopted in more 90 leading hospitals, noted the company.

Elixir Medical stated that during the initial phase of the LithiX HC-IVL system’s launch, the device demonstrated high deliverability, allowing for treatment of tortuous coronary anatomies, and success in treating a broad range of calcified plaque morphologies such as eccentric, nodular, and concentric calcium, enabling excellent final lesion expansion.

“LithiX quickly became our primary calcium modification tool,” commented Tamil Selvan Muthusamy, MBBS, in the company’s press release.

Dr. Muthusamy, who is from the Cardiac Vascular Sentral Kuala Lumpur (CVSKL) Hospital in Kuala Lumpur, Malaysia, continued, “As a high-volume center, we value its effectiveness and versatility, enabling us to treat the most complex calcified lesions in patients with advanced heart disease, as well as its cost effectiveness in our practice through reduced use of additional calcium modification devices and a simpler procedure flow.”

Additionally, Elixir announced that CVSKL Hospital has conducted an investigator-initiated study of 100 patients treated with the LithiX HC-IVL system. The results, including analysis with intravascular imaging, will be presented in the Innovation session on October 27 at TCT 2025, noted the company.